Clinical Research in Southampton
Southampton Children's Hospital

A A A Text only | Accessibility | Privacy and cookies

Home
About the Trust
Our services
Patients and visitors
Our hospitals
Education
Research
Working here
Contact us

Browse site A to Z

A
B
C
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z

Search results

Go To Simple Search

Search Type: Criteria:

You could also try: vulnerable (87), liable (19), prone (39), disposed (84), inclined (10), subject (190), receptive (3)

Doctor urges parents to avoid over-the-counter cough medicines for children

Description: A Southampton doctor has urged parents to avoid using over-the-counter cough syrups and medicines to treat coughs and colds
Url: /AboutTheTrust/Newsandpublications/Latestnews/2017/December-2017/Doctor-urges-parents-to-avoid-over-the-counter-cough-medicines-for-children.aspx

James Ashton

Description: Auto Generated Title Congratulations to Dr James Ashton, who has been awarded a clinical research training fellowship by the childre
Url: /ClinicalResearchinSouthampton/For-researchers/Education-and-training/Careerpathways/Inspirational-career-stories/James-Ashton.aspx

Congenital cytomegalovirus (CMV) and hearing loss - patient information

Description: This factsheet explains what congenital cytomegalovirus (CMV) is and how it mayaffect your child's hearing.
Url: /Media/UHS-website-2019/Patientinformation/Audiology/Congenital-cytomegalovirus-CMV-and-hearing-loss-2740-PIL.pdf

MUTYH associated polyposis (MAP) - patient information

Description: This booklet contains information about a condition called MUTYH associated polyposis (MAP).
Url: /Media/UHS-website-2019/Patientinformation/Genetics/MUTYH-associated-polyposis-MAP-3201-PIL.pdf

Meningitis trial_frequently asked questions

Description: F.A.Q.: Human nasopharyngeal colonization using a genetically modified strain of the bacteria, Neisseria lactamica This
Url: /Media/Southampton-Clinical-Research/Researchtrials/Meningitis-trial-frequently-asked-questions.pdf

Erdafitinib

Description: Regimen • Urothelial - Erdafitinib Chemotherapy Protocol UROTHELIAL CANCER ERDAFITINIB Indication • Monotherapy treatment of unresectable or metastatic urothelial cancer harbouring a susceptible fibroblast
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Bladdercancer/Erdafitinib.pdf

Carboplatin(AUC6)Docetaxel

Description: Chemotherapy Protocol BREAST CANCER CARBOPLATIN (AUC6)-DOCETAXEL Regimen • Breast Cancer – Carboplatin (AUC6)-Docetaxel Indication • Neo-adjuvant or a
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Breastcancer/CarboplatinAUC6Docetaxel.pdf

Lenvatinib(60kg or greater)

Description: Chemotherapy Protocol HEPATOCELLULAR CANCER LENVATINIB (60kg or greater) Regimen • Hepatocellular – Lenvatinib Indication • Lenva
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Hepatobiliary/Lenvatinib-60kg-or-greater-Ver1.pdf

Lenvatinib(59kg or less)

Description: Chemotherapy Protocol HEPATOCELLULAR CANCER LENVATINIB (59kg or less) Regimen • Hepatocellular – Lenvatinib Indication • Lenvatin
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Hepatobiliary/Lenvatinib-59kg-or-less-.pdf

Appendix B - VZIG risk assessment and prescription form

Description: Varicella zoster Immunoglobulin for post-exposure prophylaxis (PEP)Please note that UHS Pharmacy will issue VZIG only when bo
Url: /Media/UHS-website-2019/Docs/Post-Exposure-Prophylaxis-Policy/AppendixB-VZIGRiskAssessmentandPrescriptionForm.pdf

1 to 10 of 13

Previous 1 2 Next